• Recai Türkoğlu, Mehmet Gencer, Duygu Ekmekçi, Canan Ulusoy, Ece Erdağ, Elçin Sehitoğlu, Filiz Cavuş, Hazal Haytural, Melike Küçükerden, Nazlı Yalçınkaya, Selin Turan, Deniz Akbaş-Demir, Arzu Coban, Burçak Vural, and Erdem Tüzün.
• Department of Neurology, Haydarpasa Numune Education and Research Hospital, Istanbul University, Istanbul, Turkey.
• Med Princ Pract. 2014 Jan 1; 23 (3): 239-45.

ObjectiveThis study was conducted to identify a biomarker for multiple sclerosis (MS) that can be used as a predictor of relapse and disability.Materials And MethodsSera of 26 consecutive relapsing-remitting MS (RRMS) patients were screened for switch-associated protein 70 (SWAP-70) antibody, which was previously identified by protein macroarray. The serum levels of several cytokines, chemokines and soluble adhesion molecules related to MS attacks were measured by enzyme-linked immunosorbent assay (ELISA). A possible correlation was sought among levels of SWAP-70 antibody, measured humoral factors and disability scores.ResultsELISA studies showed high-titre SWAP-70 antibodies in 16 (61.5%) RRMS sera obtained during the attack period and 9 (34.6%) sera obtained during remission. There was a significant inverse correlation between SWAP-70 antibody levels and expanded disability status scale scores, CXCL10, soluble VCAM-1, CXCL13 and soluble VLA-4 levels.ConclusionOur results showed that SWAP-70 antibodies could potentially be utilized as relapse and prognostic biomarkers in MS. Whether or not SWAP-70 antibodies have any effect on disease mechanisms requires further investigation.© 2014 S. Karger AG, Basel.

22 keywords...

hide…